April 24, 2014     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
News Sectors
Health & Med
IT & Internet
Real Estate
Science & Research
Annual Reports
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
Terms of Use

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. 

Company Headquarters 4-6-10 Koishikawa, Bunkyo-ku,Tokyo 112-8088, JAPAN 
Company Telephone +81-3-3817-3724 
Company Stock Code - TSE
 CompanyStock Price - TSE   
Company Stock Code - U.S.
 CompanyStock Price - U.S.
Company CEO Haruo Naito 
Company Sector Alternative Energy 
Company Industries Pharmaceutical
Company Established 1941 
Company Listed 1961 
Company Homepage www.eisai.com
Company Annual Report
Company CSR Report

Headline News for Eisai  

No records were found in the Headlines


Press Releases for Eisai  

Eisai CEO Haruo Naito Appointed Knight Commander of British Empire (Apr 15, 2014)

Eisai Launches New Energy Drink "Joma" (Apr 7, 2014)

Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS) (Mar 25, 2014)

Eisai Enters Collaboration with Liverpool School of Tropical Medicine and University of Liverpool to Discover Novel Anti-Wolbachia Targeted Anti-Filarial Drugs (Mar 20, 2014)

Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan (Feb 13, 2014)

Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer (Feb 3, 2014)

Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan (Feb 3, 2014)

Eisai Announces Launch of New "Crystal Veil Mask Bokin 24 Mint" Face Mask Spray Containing Long-acting Antimicrobial Agent Etak (Jan 22, 2014)

Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. (Jan 6, 2014)

Eisai to Present New Research on Halaven (Eribulin) at 36th Annual San Antonio Breast Cancer Symposium (Dec 5, 2013)

Notification Regarding Execution of Business Transfer Agreement to Transfer Business Operations at Eisai Misato Plant to Bushu Pharmaceuticals Ltd. (Nov 29, 2013)

Eisai Submits Application for Proton Pump Inhibitor Pariet in Japan (Nov 28, 2013)

Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs (Nov 25, 2013)

Eisai to Receive Japan Marketing Authorization Holder License from Nobelpharma for Antineoplastic Agent Gliadel 7.7mg Implant (Nov 25, 2013)

Eisai Announces Launch Of New "Crystal Veil Fuite Bokin 24" Wet Wipes (Nov 20, 2013)

Eisai Makes Donation to Victims of Typhoon Haiyan in the Philippines (Nov 12, 2013)

Eisai Expands Marketing and Supply Agreement for Antiobesity Agent Lorcaserin to Include Most Countries Worldwide (Nov 8, 2013)

Eisai Enters Global Agreement with Broad Institute to Develop New Drugs for Neglected Tropical Diseases and Tuberculosis (Nov 8, 2013)

Eisai Submits Application to Expand Indication of Anti-Alzheimer's Agent Aricept(R) as Treatment for Dementia with Lewy Bodies in Japan (Oct 31, 2013)

Eisai Begins Free Supply of Diethylcarbamazine In Line With Its Global Commitment to Eliminate Lymphatic Filariasis (Oct 29, 2013)

Previous... More...



• Register for News Alerts about Eisai here

• Back to Previous Page

• View more Company Profile Listings

Photo News

A*STAR Scientists Create Stem Cells From a Drop of Blood
More >> 
Annual Reports

  More >>    
CSR Reports

  More >> 

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)